MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, CPIX made $9,131,317 in revenue. -$3,289,639 in net income. Net profit margin of -36.03%.

Income Overview

Revenue
$9,131,317
Net Income
-$3,289,639
Net Profit Margin
-36.03%
EPS
-$0.22
Unit: Dollar
Revenue Breakdown
    • Product Sancuso
    • Product Vibativ
    • Product Talicia
    • Others

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net revenues
9,131,317 15,816,928.5* 8,292,362 10,837,363
Cost of products sold
1,933,889 2,166,983.5* 988,760 2,011,389
Selling and marketing
5,064,875 6,111,936* 4,433,831 4,223,647
Research and development
1,458,436 1,483,849* 1,253,367 1,468,399
General and administrative
2,554,475 3,776,427* 2,572,066 2,874,922
Amortization
1,248,934 1,010,534* 1,009,598 1,006,484
Total costs and expenses
12,260,609 14,549,729.5* 10,257,622 11,584,841
Operating income (gain)
-3,129,292 1,267,199* -1,965,260 -747,478
Interest income
78,031 88,140* 131,583 127,489
Other income - gain on insurance proceeds
-0* 0 -
Interest expense
85,839 167,121* 109,699 109,547
Loss before income taxes
---1,943,376 -729,536
Income (loss) before income taxes
-3,137,100 1,188,218* --
Income tax expense
3,871 23,244.5* 5,670 5,671
Co-commercialization investment loss
-146,080 -3,305* --
Net income (gain)
-3,287,051 1,161,668.5* -1,949,046 -735,207
Net loss (income) at subsidiary attributable to noncontrolling interests
2,588 -24,459.5* -8,282 5,533
Net income (gain) attributable to common shareholders
-3,289,639 1,186,128 -1,940,764 -740,740
Basic EPS
-0.22 0.081 -0.13 -0.05
Diluted EPS
-0.22 0.081 -0.13 -0.05
Basic Average Shares
14,960,210 14,644,727 14,958,534 14,960,596
Diluted Average Shares
14,960,210 14,644,727 14,958,534 14,960,596
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net income (gain)attributable to common...-$3,289,639 Net income (gain)-$3,287,051 Net loss (income) atsubsidiary attributable to...$2,588 Income (loss) beforeincome taxes-$3,137,100 Co-commercialization investment loss-$146,080 Income tax expense$3,871 Interest income$78,031 Product Sancuso$2,928,634 Product Vibativ$2,118,295 Product Talicia$1,916,481 Product Kristalose$981,483 Product Caldolor$965,564 Product Other$168,850 Product Acetadote$51,981 Revenues, includingadjustments-Product Omeclamox Pak$517 Revenues, includingadjustments-Product Vaprisol$1 Operating income (gain)-$3,129,292 Interest expense$85,839 Net revenues$9,131,317 Revenues, includingadjustments-Product Redi Trex-$489 Total costs andexpenses$12,260,609 Selling and marketing$5,064,875 General andadministrative$2,554,475 Cost of products sold$1,933,889 Research and development$1,458,436 Amortization$1,248,934

CUMBERLAND PHARMACEUTICALS INC (CPIX)

CUMBERLAND PHARMACEUTICALS INC (CPIX)